Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

Pfizer has successfully acquired obesity drug developer Metsera for over $10 billion, or $86.25 per share, following a competitive bidding war with Novo Nordisk, which withdrew its offer amid antitrust concerns. This strategic acquisition, representing a 160% premium, re-establishes Pfizer in the lucrative obesity market by adding four clinical-stage programs to its pipeline after its previous internal candidate failed. While the deal is expected to be dilutive to Pfizer's adjusted EPS by approximately 16 cents in 2026 and through 2030, it positions the company for long-term growth in a high-demand therapeutic area.

Analysis

Pfizer has successfully acquired Metsera for over $10 billion, or $86.25 per share, concluding a competitive bidding war with Novo Nordisk. This acquisition, representing a substantial 160% premium, received unanimous board approval and FTC clearance, positioning it for a swift close. The deal strategically re-establishes Pfizer in the lucrative obesity market, adding four clinical-stage programs to its pipeline after its internal GLP-1 candidate, danuglipron, was discontinued earlier this year.

The Metsera acquisition is expected to be dilutive to Pfizer's adjusted EPS by approximately 16 cents in 2026 and remain dilutive through 2030, with no impact on 2025 guidance. The acquired pipeline includes MET-097i, a weekly/monthly injectable GLP-1 RA in Phase II, an ultra-long-acting amylin analog (MET-233i in Phase I), and two oral GLP-1 RA candidates, bolstering Pfizer's presence in the high-growth cardiometabolic disease space.

Pfizer's stock has declined 7.9% year-to-date against an industry increase of 6.4%, yet its valuation appears attractive at 7.8x forward earnings, below the industry average of 15.57x and its 5-year mean of 10.52x. Despite near-term EPS dilution, analyst consensus estimates for 2025 and 2026 EPS have seen slight upward revisions, reflecting a cautiously optimistic outlook on the long-term strategic benefits.

Key Decisions for Investors

• Monitor Pfizer's integration of Metsera's pipeline and the clinical progress of its obesity programs, particularly MET-097i and MET-233i, as these will be key drivers for future revenue growth
• Evaluate the impact of the anticipated EPS dilution through 2030 against the long-term strategic value and potential market share gains in the highly competitive obesity drug market
• Consider Pfizer's current valuation, which appears attractive relative to its industry and historical averages, but acknowledge the near-term financial headwinds from the acquisition